Immunovant (NASDAQ:IMVT) Rating Reiterated by Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report released on Friday morning, PriceTargets.com reports. Several other research firms have also weighed in on IMVT. Bank of America lifted their price target on Immunovant from $49.00 to $51.00 and gave the company a buy rating in a […]
More Stories
What is the Release Date for GTA 6? System Requirements and Updated Features
GTA 6 is finally arriving! After years of delays and speculation, Rockstar finally confirmed the game’s launch by the end...
Upcoming Korean Drama: 100 Days of Deception Release Date, Plot, and More
K-drama fans have been longing for a historical action-romance series. Are you also one of those fans who are desperately...
Custom Web Application Development Process: Benefits, Example, Process, and Cost
For a developing business, it sometimes becomes difficult to manage spreadsheets, teams, and SaaS tools. Are you also facing the...
Netflix’s Upcoming Documentary: A Child of My Own Release Date and More
Are you also interested in watching the real-life documentary? If yes, then this blog is for you. One of the...
Announcement! 1670 Season 4 is Releasing Soon! Release Date, Trailer Updates, and More
Hello! Polish TV series and movie fans. 1670 is going to end soon. With great reviews and huge viewership, the...
Semrush vs Serpstat vs Ahrefs: Which Is Better?
No business today can skip search engine optimization if they want to lead in the online marketplace. From keyword research...